Table 1.
Characteristic | Total (N = 4624) | Patients Who Had the Composite Outcome (n = 2084) | Patients Who Did Not Have the Composite Outcome (n = 2540) |
---|---|---|---|
Age, y, mean (SD) | 64.3 (11.3) | 65.4 (11.3) | 63.3 (11.1) |
Male sex | 4466 (96.6) | 2016 (96.7) | 2450 (96.5) |
Race | |||
White | 3391 (73.3) | 1531 (73.5) | 1860 (73.2) |
Black | 830 (18.0) | 355 (17.0) | 475 (18.7) |
Other | 403 (8.7) | 198 (9.5) | 205 (8.1) |
BMI, kg/m2 | |||
Underweight (BMI <20) | 44 (1.1) | 25 (1.3) | 19 (0.9) |
Normal (BMI ≥20 and <25) | 541 (13.2) | 291 (15.6) | 250 (11.2) |
Overweight (BMI ≥25 and <30) | 1161 (28.4) | 519 (27.8) | 642 (28.8) |
Obese (BMI = 30) | 2346 (57.3) | 1030 (55.2) | 1316 (59.1) |
Geographic area | |||
Northeast | 605 (13.1) | 248 (11.9) | 357 (14.1) |
South | 1778 (38.5) | 793 (38.1) | 985 (38.8) |
Central | 1271 (27.5) | 585 (28.1) | 686 (27.0) |
West | 970 (21.0) | 458 (22.0) | 512 (20.2) |
Year of PJI | |||
2003–2004 | 401 (8.7) | 202 (9.7) | 199 (7.8) |
2005–2007 | 820 (17.7) | 387 (18.6) | 433 (17.1) |
2008–2010 | 857 (18.5) | 406 (19.5) | 451 (17.8) |
2011–2013 | 828 (17.9) | 357 (17.1) | 471 (18.5) |
2014–2016 | 820 (17.7) | 354 (17.0) | 466 (18.4) |
2017–2019 | 898 (19.4) | 378 (18.1) | 520 (20.5) |
Joint | |||
Knee | 3779 (81.7) | 1706 (81.9) | 2073 (81.6) |
Hip | 813 (17.6) | 362 (17.4) | 451 (17.8) |
Timing of PJI from previous joint surgery | |||
Early (within 90 d) | 1150 (24.9) | 445 (21.4) | 705 (27.7) |
Late (after 90 d) | 1056 (22.8) | 458 (22.0) | 598 (23.5) |
Unknown | 2418 (52.3) | 1181 (56.7) | 1237 (48.7) |
Modified APACHE III score | |||
≤21 | 3276 (70.9) | 1285 (61.7) | 1991 (78.4) |
22–32 | 902 (19.5) | 511 (24.5) | 391 (15.4) |
33–45 | 341 (7.4) | 209 (10.0) | 132 (5.2) |
>45 | 105 (2.3) | 79 (3.8) | 26 (1.0) |
Staphylococcus aureus susceptibility | |||
MSSA | 3405 (73.6) | 1456 (69.9) | 1949 (76.7) |
MRSA | 1219 (26.4) | 628 (30.1) | 591 (23.3) |
Polymicrobial infection | 1111 (24.3) | 485 (23.9) | 626 (24.7) |
Comorbidities | |||
Myocardial infarction | 367 (8.0) | 198 (9.5) | 169 (6.7) |
Congestive heart failure | 755 (16.4) | 457 (22.0) | 298 (11.8) |
COPD | 1433 (31.2) | 699 (33.7) | 734 (29.1) |
Peripheral vascular disease | 925 (20.1) | 528 (25.4) | 397 (15.8) |
Cerebrovascular disease | 665 (14.5) | 341 (16.4) | 324 (12.9) |
Dementia | 86 (1.9) | 41 (2.0) | 45 (1.8) |
Hemiplegia | 160 (3.5) | 98 (4.7) | 62 (2.5) |
Autoimmune disease | 294 (6.4) | 153 (7.4) | 141 (5.6) |
Diabetes mellitus | 1792 (39.0) | 929 (44.8) | 863 (34.3) |
Peptic ulcer | 253 (5.5) | 137 (6.6) | 116 (4.6) |
Liver disease | 670 (14.6) | 362 (17.4) | 308 (12.2) |
Chronic kidney disease | 648 (14.1) | 376 (18.1) | 272 (10.8) |
Solid cancer | 805 (17.5) | 433 (20.9) | 372 (14.8) |
Hematologic malignancy | 106 (2.3) | 69 (3.3) | 37 (1.5) |
HIV/AIDS | 51 (1.1) | 27 (1.3) | 24 (1.0) |
Duration of rifampin treatment from day 15 after DAIR | |||
0 d | 3782 (81.8) | 1742 (83.6) | 2040 (80.3) |
1–90 d | 610 (13.2) | 290 (13.9) | 320 (12.6) |
91–180 d | 143 (3.1) | 33 (1.6) | 110 (4.3) |
181–731 d | 89 (1.9) | 19 (0.9) | 70 (2.8) |
Duration of antibiotic treatment from day 15 after DAIR | |||
≤90 | 3602 (77.9) | 1802 (86.5) | 1800 (70.9) |
91–180 d | 286 (6.2) | 114 (5.5) | 172 (6.8) |
181–270 d | 164 (3.6) | 62 (3.0) | 102 (4.0) |
≥271 d | 572 (12.4) | 106 (5.1) | 466 (18.4) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; DAIR, debridement, antibiotics, and implant retention; HIV, human immunodeficiency virus; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; PJI, prosthetic joint infection; SD, standard deviation.